Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Block listing application

13 May 2010 14:38

RNS Number : 8875L
ReNeuron Group plc
13 May 2010
 



Block listing application

 

 

Guildford, UK, 13 May 2010: ReNeuron Group plc ("Company") (LSE: RENE.L) today announces that application has been made to the London Stock Exchange plc for a block listing totaling 2,000,000 ordinary shares of 1p each in the capital of the Company ("Shares"). These Shares shall be allotted from time to time pursuant to the vesting of awards under the Company's Share Option Schemes and share-based payments falling due to third parties under pre-existing agreements. These shares shall rank equally with the Company's existing issued ordinary shares.

 

 

Enquiries:

 

Michael Hunt, Chief Executive Officer

ReNeuron Group plc

 

+44 (0) 1483 302560

Simon Leathers, Emma Earl

Daniel Stewart & Company plc

 

+44 (0) 20 7776 6550

Alastair Stratton, Tim Graham

Matrix Corporate Capital LLP

 

+44 (0) 20 3206 7000

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSFIFDDFSSEDI
Date   Source Headline
18th Nov 20217:00 amRNSNotice of Results
1st Nov 20217:00 amRNSTotal Voting Rights
26th Oct 20213:09 pmRNSDirector exit arrangements
26th Oct 20217:00 amRNSCollaboration agreement with UCL
21st Oct 20217:00 amRNSDirector Share Purchase
20th Oct 20217:00 amRNSDirector/PDMR Interest in Share Options
18th Oct 20217:00 amRNSFurther changes in the Board of Directors
18th Oct 20217:00 amRNSFirst subject treated at Oxford Eye Hospital
12th Oct 20212:05 pmRNSSecond Price Monitoring Extn
12th Oct 20212:01 pmRNSPrice Monitoring Extension
11th Oct 20214:40 pmRNSSecond Price Monitoring Extn
11th Oct 20214:35 pmRNSPrice Monitoring Extension
11th Oct 20212:06 pmRNSSecond Price Monitoring Extn
11th Oct 20212:00 pmRNSPrice Monitoring Extension
11th Oct 202111:05 amRNSSecond Price Monitoring Extn
11th Oct 202111:00 amRNSPrice Monitoring Extension
11th Oct 20219:05 amRNSSecond Price Monitoring Extn
11th Oct 20219:00 amRNSPrice Monitoring Extension
11th Oct 20217:00 amRNSPositive data generated in exosome collaboration
1st Oct 20217:00 amRNSRegulatory approval for continuation of RP trial
16th Sep 20214:26 pmRNSResult of AGM
2nd Sep 202112:00 pmRNSBlock Listing Review, Application and TVR
16th Aug 20212:20 pmRNSPosting of AR and Accounts and Notice of AGM
6th Aug 20217:00 amRNSDirectorate Change
14th Jul 20217:00 amRNSBoard Change
8th Jul 20217:00 amRNSPreliminary Results for the year ended 31 March 21
2nd Jul 20211:00 pmRNSNotice of Results
2nd Jul 20217:00 amRNSNotice of Results
1st Jul 20217:00 amRNSDirectorate Change
1st Jul 20217:00 amRNSTotal Voting Rights
18th Jun 202110:48 amRNSHolding(s) in Company
9th Jun 20214:36 pmRNSPrice Monitoring Extension
9th Jun 20212:05 pmRNSSecond Price Monitoring Extn
9th Jun 20212:00 pmRNSPrice Monitoring Extension
9th Jun 202111:55 amRNSUpdate for hRPC therapy candidate study
7th Jun 20215:25 pmRNSHolding(s) in Company
20th May 20217:00 amRNSAppointment of Chief Scientific Officer
4th May 20217:00 amRNSTotal Voting Rights
29th Apr 20217:00 amRNSInitiation of research by Allenby Capital
6th Apr 20217:00 amRNSVirtual conference attendance and presentations
30th Mar 20217:00 amRNSHolding(s) in Company
19th Mar 20217:00 amRNSExosome platform update
16th Mar 20214:05 pmRNSHolding(s) in Company
16th Mar 202110:57 amRNSHolding(s) in Company
16th Mar 20217:00 amRNSHolding(s) in Company
12th Mar 20217:00 amRNSDirectorate Change
1st Mar 20217:00 amRNSBlock Listing Review and Total Voting Rights
25th Feb 20217:01 amRNSInvestor presentations
25th Feb 20217:00 amRNSAppointment of Joint Broker
11th Feb 20217:00 amRNSDirector/PDMR Interest in Shares and Share Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.